{
  "id": 20452005,
  "title": "In Erwartung riesiger Umsätze: Roche nimmt mit neuem Brustkrebsmedikament die erste Hürde",
  "url": "https://urgent.news/2026/11/17/in-erwartung-riesiger-umsatze-roche-nimmt-mit-neuem",
  "topic": "business",
  "section": "Business",
  "published": "2026-11-17T15:39:17.000Z",
  "source": {
    "name": "NZZ Wirtschaft",
    "slug": "nzz-wirtschaft",
    "url": "https://www.nzz.ch/wirtschaft/in-erwartung-riesiger-umsaetze-roche-nimmt-mit-neuem-brustkrebsmedikament-die-erste-huerde-ld.10066453"
  },
  "original_language": "de",
  "account": "Roche, the Swiss pharmaceutical company, hopes its new breast cancer medication Giredestrant will become its most profitable product in history. The company has high hopes for the drug, which is expected to treat about 70% of breast cancer patients worldwide. The FDA granted approval for Giredestrant's first treatment method, allowing it to be prescribed to women with advanced breast cancer - a group making up 10% of potential patients with metastases. Roche anticipates approval for the second treatment method, targeting early-stage breast cancer patients, by the end of November in the US. Overall, the drug is expected to reach 70% of all breast cancer cases. While Roche expects the drug to generate $14 billion in annual sales by 2033, analysts at UBS predict sales will only reach $4.2 billion by then. Despite Roche's confidence in the drug's potential, it remains to be seen how widely physicians will prescribe the new treatment.",
  "summary": "Für den Pharmakonzern Roche soll es das umsatzstärkste Medikament in seiner Geschichte werden. Auch Anleger machen sich grosse Hoffnungen zu Giredestrant.",
  "key_points": [
    "Roche develops new breast cancer medication Giredestrant",
    "FDA approves first treatment method for advanced breast cancer",
    "Roche anticipates $14 billion annual sales by 2033"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}